| Active Pharmaceutical Ingredients (API) | Bulk drug manufacturing of key APIs such as diloxanide furoate, sulphadiazine, ciprofloxacin, and ranitidine HCl. | Established manufacturing facilities, global client base, and regulatory compliance. | B2B; pharmaceutical manufacturers across Asia, Americas, and Africa. | Specialty APIs and products with limited competition. | 125 | 99 | Revenue generated mainly through sales of APIs to pharmaceutical companies globally. | Direct sales based on volume contracts and long-term client relationships. | Global demand for affordable APIs, expansion of production capacity, and regulatory approvals. | |
| Finished Dosage Formulations | Development and marketing of pain relief and anti-histamine branded formulations. | New brands with growth potential and existing manufacturing capabilities. | B2B and B2C, targeting healthcare providers and patients in India. | Branded formulations with intellectual property potential. | 0 | 1 | Revenue from product sales to pharmaceutical distributors and retailers. | Branded product sales with competitive pricing strategies. | Brand launches and market penetration in therapeutic segments. | ENERLIN, SOLSITA, TRANVIA P, YAMONT LC |
